With an aim to strengthen Zentiva's position in the UK, the company has acquired Creo Pharmaceuticals. The move is expected to bring value to the firm’s customers and patients in the country.
Prague/Czech Republic – Zentiva Group has recently announced the acquisition of Creo Pharmaceuticals in the UK, a subsidiary of Amneal Pharmaceuticals.
Nick Haggar, CEO of Zentiva stated: "Zentiva is delighted to confirm the acquisition of Creo Pharma which will strengthen Zentiva's position in the UK. This move reflects our confidence in the UK and our deep commitment to the development, manufacture and supply of high-quality affordable medicines. We welcome the Creo Pharma team that has a strong reputation for providing high-quality services to their customers."
"We are happy to join Zentiva as we are convinced that the combination of our two businesses will bring value to our customers and to patients in the UK. We believe the combination of Creo and Zentiva will allow us to accelerate our growth and achieve our full potential," said Luke Hart, Managing Director of Creo Pharmaceuticals.